At 13.6% CAGR, the Middle East & Africa Antibody Drug Conjugates Market is Projected to be Worth US$ 201.29 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Middle East & Africa antibody drug conjugates market was valued at US$ 72.73 million in 2022 and is expected to reach US$ 201.29 million by 2030, registering a CAGR of 13.6% from 2022 to 2030. Escalating pipeline of ADCs and rising incidences of cancer are among the critical factors attributed to the Middle East & Africa antibody drug conjugates market expansion.

Various biopharmaceutical companies are developing ADCs owing to the rising interest in ADCs as promising cancer treatment. Companies such as ImmunoGen, Inc; NBE-Therapeutics, Seagen Inc; ADC Therapeutics; Merck KGaA; Sorrento Therapeutics, Inc; Mythic Therapeutics; Sutro Biopharma; Peak Bio; Regeneron Pharmaceuticals; Asana BioSciences; Sanofi; Navrogen, Inc; and OBI Pharma have ADCs in the different developmental phases. It is anticipated that the commercial launch of the ADCs developed will significantly enhance market size.

The companies have developed a broad list of promising ADCs in the different clinical stages and pipelines to be commercialized. The list of ADCs in the pipeline includes Camidanlumab tesirine, ADCT-602, Zynlonta, ADCT-901, ADCT-701, ADCT-212, ADCT-601, Ladiratuzumab Vedotin, NBE-002, IMGN151, IMGN-632, IMGC 936, IMGN-151, OBI 999, R 992, NAV-001, MYTX-011, M1231, STI-6129, Torpedo, BCMA ADC, REGN5093-M114, ASN004, TR 1801 ADC.

Companies have also shared pre-clinical data related to their respective products. For instance, in April 2023, Mythic Therapeutics announced preclinical data for its MYTX-011 (cMET-targeting ADC). The data published included the highlights of MYTX-011 intended to treat a broad range of cMET+ cancers. Likewise, at the Association for Cancer Research Annual Meeting in April 2023, Araris Biotech AG announced its preclinical data on anti-Nectin-4 and anti-HER2 ADCs. The two ADCs were developed using the companys proprietary linker technology. The data demonstrated improved anti-tumor activity of anti-Nectin-4 and anti-HER2 ADCs compared to respective FDA-approved ADCs in head-to-head in-vivo studies. Thus, the rise in innovative ADCs will likely propel the market growth exponentially in the coming years.

On the contrary, high cost of ADCs development and commercialization hampers the growth Middle East & Africa antibody drug conjugates market.

Based on technology, the Middle East & Africa antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 67.5% share of the Middle East & Africa antibody drug conjugates market in 2022, amassing US$ 49.12 million. It is projected to garner US$ 134.20 million by 2030 to expand at 13.4% CAGR during 2022-2030.

Based on application, the Middle East & Africa antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 54.6% share of the Middle East & Africa antibody drug conjugates market in 2022, amassing US$ 39.73 million. It is projected to garner US$ 113.41 million by 2030 to expand at 14.0% CAGR during 2022-2030.

Based on distribution channel, the Middle East & Africa antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 62.4% share of Middle East & Africa antibody drug conjugates market in 2022, amassing US$ 45.37 million. It is projected to garner US$ 129.21 million by 2030 to expand at 14.0% CAGR during 2022-2030.

Based on country, the Middle East & Africa antibody drug conjugates market is categorized into South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Saudi Arabia held 37.8% share of Middle East & Africa antibody drug conjugates market in 2022, amassing US$ 27.49 million. It is projected to garner US$ 80.51 million by 2030 to expand at 14.4% CAGR during 2022-2030.

Key players operating in the Middle East & Africa antibody drug conjugates market are Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, and Astellas Pharma Inc, among others.

- In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.

- In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagens world-class expertise and knowledge of ADC development, manufacturing and commercialization to maximize the potential of disitamab vedotin.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com